409 related articles for article (PubMed ID: 22908014)
1. The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.
Pauls SD; Lafarge ST; Landego I; Zhang T; Marshall AJ
Front Immunol; 2012; 3():224. PubMed ID: 22908014
[TBL] [Abstract][Full Text] [Related]
2. p110δ phosphoinositide 3-kinase represses IgE switch by potentiating BCL6 expression.
Zhang TT; Makondo KJ; Marshall AJ
J Immunol; 2012 Apr; 188(8):3700-8. PubMed ID: 22422878
[TBL] [Abstract][Full Text] [Related]
3. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
4. Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production.
Zhang TT; Okkenhaug K; Nashed BF; Puri KD; Knight ZA; Shokat KM; Vanhaesebroeck B; Marshall AJ
J Allergy Clin Immunol; 2008 Oct; 122(4):811-819.e2. PubMed ID: 19014771
[TBL] [Abstract][Full Text] [Related]
5. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases.
Miletic AV; Anzelon-Mills AN; Mills DM; Omori SA; Pedersen IM; Shin DM; Ravetch JV; Bolland S; Morse HC; Rickert RC
J Exp Med; 2010 Oct; 207(11):2407-20. PubMed ID: 20956547
[TBL] [Abstract][Full Text] [Related]
6. Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway.
Marshall AJ; Niiro H; Yun TJ; Clark EA
Immunol Rev; 2000 Aug; 176():30-46. PubMed ID: 11043766
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol (3,4) bisphosphate-specific phosphatases and effector proteins: A distinct branch of PI3K signaling.
Li H; Marshall AJ
Cell Signal; 2015 Sep; 27(9):1789-98. PubMed ID: 26022180
[TBL] [Abstract][Full Text] [Related]
8. Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Aydin E; Faehling S; Saleh M; Llaó Cid L; Seiffert M; Roessner PM
Front Immunol; 2020; 11():595818. PubMed ID: 33552053
[TBL] [Abstract][Full Text] [Related]
9. The SH2 domain-containing inositol 5'-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcgammaRIIb1-mediated inhibition of B cell receptor signaling.
Gupta N; Scharenberg AM; Fruman DA; Cantley LC; Kinet JP; Long EO
J Biol Chem; 1999 Mar; 274(11):7489-94. PubMed ID: 10066815
[TBL] [Abstract][Full Text] [Related]
10. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation.
Baracho GV; Miletic AV; Omori SA; Cato MH; Rickert RC
Curr Opin Immunol; 2011 Apr; 23(2):178-83. PubMed ID: 21277760
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.
Puri KD; Gold MR
Front Immunol; 2012; 3():256. PubMed ID: 22936933
[TBL] [Abstract][Full Text] [Related]
12. Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy.
Browne CD; Del Nagro CJ; Cato MH; Dengler HS; Rickert RC
Immunity; 2009 Nov; 31(5):749-60. PubMed ID: 19896393
[TBL] [Abstract][Full Text] [Related]
13. Regulation of T-cell responses by PTEN.
Buckler JL; Liu X; Turka LA
Immunol Rev; 2008 Aug; 224():239-48. PubMed ID: 18759931
[TBL] [Abstract][Full Text] [Related]
14. Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.
Rodgers SJ; Ferguson DT; Mitchell CA; Ooms LM
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28082369
[TBL] [Abstract][Full Text] [Related]
15. Requirement for phosphoinositide 3-kinase p110delta signaling in B cell antigen receptor-mediated antigen presentation.
Al-Alwan MM; Okkenhaug K; Vanhaesebroeck B; Hayflick JS; Marshall AJ
J Immunol; 2007 Feb; 178(4):2328-35. PubMed ID: 17277138
[TBL] [Abstract][Full Text] [Related]
16. Two distinct waves of membrane-proximal B cell antigen receptor signaling differentially regulated by Src homology 2-containing inositol polyphosphate 5-phosphatase.
Krahn AK; Ma K; Hou S; Duronio V; Marshall AJ
J Immunol; 2004 Jan; 172(1):331-9. PubMed ID: 14688341
[TBL] [Abstract][Full Text] [Related]
17. Phosphoinositide 3-kinase-regulated adapters in lymphocyte activation.
Zhang TT; Li H; Cheung SM; Costantini JL; Hou S; Al-Alwan M; Marshall AJ
Immunol Rev; 2009 Nov; 232(1):255-72. PubMed ID: 19909369
[TBL] [Abstract][Full Text] [Related]
18. Failed down-regulation of PI3K signaling makes autoreactive B cells receptive to bystander T cell help.
Fiske BE; Getahun A
bioRxiv; 2023 Jan; ():. PubMed ID: 36747655
[TBL] [Abstract][Full Text] [Related]
19. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
20. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
